• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Global Biosimilar Market Outlook 2020

  • ID: 3161915
  • April 2015
  • Region: Global
  • 110 pages
  • RNCOS E-Services Private Limited

FEATURED COMPANIES

  • Biocad
  • Celltrion
  • Hospira
  • Intas
  • Sandoz
  • Stada Arzneimittel
  • MORE

The much awaited biosimilars have finally entered the US pharmaceutical market with the FDA approval of Sandoz’s Zarxio, a G-CSF. The move is being hailed by biosimilar manufacturers and is expected to fuel numerous submissions in the coming days, making US a significant region for biosimilar activity. At the same time, as shrinking budgets are rooting for reduced healthcare expenditures and majority of blockbuster drugs are about to lose exclusivity, the biosimilar industry stands as the sole gainer.

This new research study titled “Global Biosimilar Market Outlook 2020”, reveals that the market, which was worth US$ 1.89 Billion in 2014, is expected to reach US$ 25.53 Billion by 2020, growing at an impressive CAGR of 54.4%. The report has been divided into numerous sections that deal with the various aspects of the market.

In the report, industry has been segmented based on the different classes of biosimilars available in the market, such as, mAbs, Insulin, Erythropoeitin (EPOs), Human Growth Hormone (HGH) and Interferons. The second segmentation divides the industry on the basis of major geographies which includes Europe, Asia-Pacific, and Others (including READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Biocad
  • Celltrion
  • Hospira
  • Intas
  • Sandoz
  • Stada Arzneimittel
  • MORE

1. Analyst View

2. Research Methodology

3. Biologics Market Outlook to 2020
3.1 Market Size
3.2 Market Segmentation

4. Global Biosimilars Market Outlook 2020
4.1 Market Size
4.2 Market Segmentation by Application
4.2.1 Erythropoietin (EPO)
4.2.2 Human Growth Hormone (HGH)
4.2.3 Granulocyte- Colony Stimulating Factor (G-CSF)
4.2.4 Monoclonal Antibody (mAb)
4.2.5 Insulin
4.2.6 Interferon (IFN)
4.3 Market Segmentation by Geography
4.3.1 Europe
4.3.2 Asia-Pacific
4.3.3 Others

5. Market Drivers and Challenges
5.1 Drivers
5.1.1 Approval of the First Biosimilar in the US Opens the Doors of a Lucrative Market
5.1.2 Shrinking Healthcare Budgets to Carve Way for Biosimilars
5.1.3 Numerous Biologic Patent Expiries Provide Opportunity for Biosimilars
5.2 Challenges
5.2.1 Need for the Development of Manufacturing Capabilities
5.2.2 Greater Litgation Risk
5.2.3 High Cost of Development Accompanied with Low Adoption
5.2.4 Interchangeability/ Substitutability

6. Market Trends and Developments
6.1 Plant based Manufacturing Platforms for Biosimilars
6.2 Developing Economies Emerge as Potential Markets for Biosimilar Production

7. Mergers and Acquisitions

8. Porters Five Forces Model

9. Competitive Landscape
9.1 Market Share of Major Players
9.2 Profiles
9.2.1 Biocad
9.2.2 Celltrion
9.2.3 Dong-A Pharmaceutical Co., Ltd
9.2.4 Hospira
9.2.5 Intas
9.2.6 Sandoz
9.2.7 Stada Arzneimittel
9.2.8 Teva

10. Future Outlook

List of Tables
Table 4-1: Global - Patent Expiry Status of EPOs
Table 4-2: Global - Biosimilar EPOs Approved for Marketing
Table 4-3: Global - Biosimilar EPOs in Pipeline
Table 4-4: Global - Biosimilar HGH Approved for Marketing
Table 4-5: Global - Biosimilar HGH in Pipeline
Table 4-6: Global - Biosimilar G-CSF Approved for Marketing
Table 4-7: Global Biosimilar G-CSF Market - Key Players by Rank
Table 4-8: Global - Biosimilar G-CSF in Pipeline
Table 4-9: Global - Patent Expiry Status of G-CSF
Table 4-10: Global - Biosimilar mAbs Approved for Marketing
Table 4-11: Global Biosimilar mAb Market - Key Players by Rank
Table 4-12: Global - Biosimilar mAbs in Pipeline
Table 4-13: Global - Patent Expiry Status of mAbs
Table 4-14: Global - Biosimilar Insulin Approved for Marketing
Table 4-15: Global Biosimilar Insulin Market - Key Players by Rank
Table 4-16: Global - Biosimilar Insulin in Pipeline
Table 4-17: Global - Patent Expiry Status of Insulin
Table 4-18: Global - Biosimilar Interferons Approved for Marketing
Table 4-19: Global - Biosimilar Interferons in Pipeline
Table 4-20: Global - Patent Expiry Status of Interferons
Table 7-1: Global - Major M&A Activity in the Past Year
Table 9-1: Biocad - Biosimilars Approved for Marketing
Table 9-2: Biocad - Biosimilars in Pipeline
Table 9-3: Biocad - Strengths & Weaknesses
Table 9-4: Celltrion - Key Financials (Million KRW), 2011-2013
Table 9-5: Celltrion - Biosimilars Approved for Marketing
Table 9-6: Celltrion - Biosimilars in Pipeline
Table 9-7: Celltrion - Strengths & Weaknesses
Table 9-8: Dong-A Pharmaceutical - Key Financials (Billion Won), 2011-2013
Table 9-9: Dong-A Pharmaceutical - Biosimilars in Pipeline
Table 9-10: Dong-A Pharmaceutical - Strengths & Weaknesses
Table 9-11: Hospira - Key Financials (Million Dollars), 2011-2013
Table 9-12: Hospira - Biosimilars Approved for Marketing
Table 9-13: Hospira - Biosimilars in Pipeline
Table 9-14: Hospira - Strengths & Weaknesses
Table 9-15: Intas - Biosimilars Approved for Marketing
Table 9-16: Intas - Biosimilars in Pipeline
Table 9-17: Intas - Strengths & Weaknesses
Table 9-18: Sandoz - Biosimilars Approved for Marketing
Table 9-19: Sandoz - Biosimilars in Pipeline
Table 9-20: Sandoz - Strengths & Weaknesses
Table 9-21: Stada - Biosimilars Approved for Marketing
Table 9-22: Stada - Biosimilars in Pipeline
Table 9-23: Stada - Strengths & Weaknesses
Table 9-24: Teva - Biosimilars Approved for Marketing
Table 9-25: Teva - Strengths & Weaknesses

List of Figures
Figure 3-1: Global - Biologics Market (Billion US$), 2014-2020
Figure 3-2: Share of Biologics in Sales of Top 100 Pharma Products
Figure 3-3: Global - Biologics Market by Segment (%), 2014
Figure 4-1: Global - Biosimilars Market (Billion US$), 2014-2020
Figure 4-2: Global - Biosimilars Market by Key Segment (%), 2014
Figure 4- 3: Global - Biosimilars Market by Key Segment (%), 2020
Figure 4-4: Global - Erythropoietin Biosimilars Market (Million US$), 2014 & 2020
Figure 4-5: Global - HGH Biosimilars Market (Million US$), 2014 & 2020
Figure 4-6: Global - G-CSF Biosimilars Market (Million US$), 2014 & 2020
Figure 4-7: Global - mAb Biosimilars Market (Million US$), 2014 & 2020
Figure 4-8: Global - Insulin Biosimilars Market (Million US$), 2014 & 2020
Figure 4-9: Global - Interferon Biosimilars Market (Million US$), 2014 & 2020
Figure 4-10: Europe - Biosimilars Market (Million US$), 2014-2020
Figure 4-11: Europe - Biosimilars Market by Country (%), 2014
Figure 4-12: Asia - Pacific - Biosimilars Market (Billion US$), 2014-2020
Figure 4-13: Asia - Pacific - Biosimilars Market by Country (%), 2014
Figure 4-14: Others - Biosimilars Market (Billion US$), 2014-2020
Figure 5-1: World’s Best Selling Biologics and their Patent Expiry in the US
Figure 9-1: Market Share of Major Players in the Biosimilar Industry, 2014
Figure 9-2: Hospira - Breakdown of Revenue by Geographic Segment (%), 2013
Figure 9-3: Hospira - Breakdown of Revenue by Industry Segment (%), 2013
Figure 9-4: Sandoz - Global Sales (Billion USD), 2011-2013
Figure 9-5: Sandoz - Breakdown of Revenue by Geographic Segment (Billion USD), 2011-2013

Note: Product cover images may vary from those shown

- Biocad
- Celltrion
- Dong-A Pharmaceutical Co., Ltd
- Hospira
- Intas
- Sandoz
- Stada Arzneimittel
- Teva

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Pfizer, Inc. Grünenthal GmbH GlaxoSmithKline PLC Abbott Laboratories Ltd. Roche Diagnostics Ltd. Novo Nordisk A/S